Archive
1250 articles, sorted by publication time.
Using cellular and humanized mouse models, a Mayo Clinic team traced the mechanism by which TRAILshort suppresses T-cell signaling through DR5 and SHP-1. Although a neutralizing antibody offers a new avenue for enhancing CAR-T therapy, human efficacy and safety still remain to be validated.
Sonesitatug vedotin prolonged overall survival in CLDN18.2-positive gastric and gastroesophageal junction cancers, but progression-free survival did not reach statistical significance; until the full data are released, the magnitude of benefit and toxicity trade-offs cannot be assessed.
A replenishable flexible device delivers natural killer cells and a cytokine through the same subcutaneous access channel while also withdrawing peritoneal fluid to track the tumor environment. The efficacy signal comes from mice, and multiple hurdles remain before human use.
A multicenter phase 2 trial found that taking dronabinol at bedtime reduced the frequency and intensity of trauma-related nightmares more effectively than placebo; this signal helps fill a treatment gap, but is not yet sufficient to make medicinal THC a routine therapy for PTSD.
Researchers conducted CRISPR screens in 162 patient-derived tumor organoids, identifying thousands of gene dependencies that sustain cancer cell survival and linking these vulnerabilities to genomic and clinical features. This open map offers a new starting point for drug-target discovery, but it cannot yet directly predict patient treatment outcomes.
HAYA is using an antisense oligonucleotide to suppress the long noncoding RNA WISPER in an effort to alter the pathological state of cardiac fibroblasts. This novel mechanism has entered early-stage human trials, but its safety and clinical benefits remain to be demonstrated.
This generative AI starts with proteins that already have established functions and rewrites both their sequences and lengths; cell experiments showed that some miniaturized versions could still fluoresce or catalyze reactions, but extensive deletions also revealed the boundary at which function is lost.
From a hypoxic placenta and failed vascular remodeling to systemic maternal immune activation, a 20-person study maps the cellular pathways of severe preeclampsia and identifies therapeutic entry points worthy of further validation.
A dendritic cell vaccine simultaneously presents tumor antigens and a fragment of the coronavirus spike protein, seeking to redirect existing helper T-cell memory to support an anticancer response; results in melanoma and breast cancer models are encouraging, but no human efficacy data are yet available.
The next-generation, implant-free minimally invasive device sequentially performs circumferential aqueous outflow canal dilation and trabeculotomy, with a U.S. launch expected in the fourth quarter of 2026; however, 510(k) clearance does not demonstrate superiority over existing procedures.
The same ambient voice tool may cross the regulatory boundary if diagnostic recommendations or automatic ordering functions are added; the UK’s new clarification makes product purpose, human review, and version updates key safety considerations in healthcare settings.
The LATA trial showed that among adolescents who had achieved viral suppression, switching to long-acting cabotegravir and rilpivirine reduced the confirmed viral rebound rate from 6.4% to 0.9%; the findings directly address the hardest barrier in daily medication—sustained treatment adherence.